Investigational Drug Service — Long Island City, New York

Investigational Drug Service is a clinical research site located in Long Island City, New York, United States 11101.

Crixeo Health Trust Score: 58/100 (POOR). This profile has not yet been claimed by the site owner.

Investigational Drug Service has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms.

Sponsors: Seagen, a wholly owned subsidiary of Pfizer.

Sponsor Feasibility Report

Trust Score: 58/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Investigational Drug Service?

Investigational Drug Service has a Crixeo Trust Score of 58/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Investigational Drug Service conducted?

Investigational Drug Service has 1 clinical trials on record, with 1 currently active. Their work covers Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms.

Is Investigational Drug Service accredited by Crixeo Health?

Investigational Drug Service has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Investigational Drug Service?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.